Summary of Study ST002383

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001533. The data can be accessed directly via it's Project DOI: 10.21228/M8J99C This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002383
Study TitleMetabolomics of B-cell Acute Lymphoblastic Leukemia in Response to Adipocyte Conditioned Media
Study TypeUntargeted MS
Study SummaryAdipocyte conditioned media (ACM), stromal cell conditioned media (SCM) and unconditioned media (UCM) were added to B-cell Acute Lymphoblastic Leukemia cells (REH and RCH-AcV) either with or without methotrexate (MTX). The metabolomic profiles of the cells was determined by mass spectrometry.
Institute
Emory University
DepartmentPediatrics
LaboratoryJoshua Chandler, PhD
Last NameChandler
First NameJoshua
Address2015 Uppergate Drive NE, Atlanta, GA 30322
Emailjoshua.chandler@emory.edu
Phone404-727-3536
Submit Date2022-10-07
Num GroupsTwo sets of two sets of three groups (MTX and no-MTX, REH and RCH-AcV, ACM vs SCM vs UCM)
Total Subjects3 replicates of each group (36 total)
Publicationssubmitted to JNCI
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2023-06-07
Release Version1
Joshua Chandler Joshua Chandler
https://dx.doi.org/10.21228/M8J99C
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:TR002484
Treatment Summary:REH and RCH-AcV were maintained in RPMI1640 (cat#10-041-CV, Corning, Glendale, AZ), supplemented with 20% FBS (cat#S11550, BioTechne, Minneapolis, MN). OP-9 bone marrow stromal cells were maintained in α-MEM (cat#15-012-CV, Corning, Glendale, AZ) supplemented with 20% FBS. For adipocyte differentiation, 105 OP-9 cells were plated in 6-well plates in DMEM (cat#10-017-CV, Corning, Glendale, AZ) supplemented with 10% FBS as previously described [18, 26]. After 24 hours of culture, the media was removed and switched to differentiation media which is composed of α-MEM supplemented with 1.8mM oleate (cat#O7501, Sigma, St. Louis, MO) bound to BSA (cat#A6003, Sigma, St. Louis, MO) with molar ratio 5.5:1 along with 175nM insulin (cat#I6634, Sigma, St. Louis, MO) and 0.2% FBS. ACM was collected after 3 days of differentiation and used in the experiments describe in this study. For SCM, OP-9 cells were plated in DMEM supplemented with 10% FBS and conditioned media were collected on day 3 of culture. Human B-ALL cell lines (REH and RCH-AcV) were cultured for 24 hours in UCM, SCM, or ACM. Additionally, methotrexate (MTX)-treated human B-ALL cells were cultured for an additional 12 hours of treatment with MTX (50nM for REH and 70 nM for RCH-AcV). This timepoint was chosen due to our prior work in this system to avoid submitting mostly apoptotic cells for analysis.
Treatment Compound:adipocyte- , stromal cell-, and un- conditioned media; methotrexate or not
Treatment Dosevolume:methotrexate: 50-70 nM
Treatment Doseduration:conditioned medias: 24 hr; methotrexate: additional 12 hr
Treatment Vehicle:methotrexate: DMSO
  logo